Research on antiepileptic drug (AED) teratogenesis has demonstrated an increased risk for valproate. The impact of these findings on current AED prescribing patterns for women of childbearing age with epilepsy is uncertain. The Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) Study is an ongoing prospective multicenter observational investigation that enrolled pregnant women with epilepsy on the most common AED monotherapies from October 1999 to February 2004 (carbamazepine, lamotrigine, valproate, and phenytoin). A 2007 survey of AED use in women of childbearing age at eight NEAD centers found a total of 932 women of childbearing age with epilepsy (6% taking no AED, 53% monotherapy, 41% polytherapy). The most common monotherapies were lamotrigine or levetiracetam. Since 2004, prescriptions of carbamazepine, phenytoin, and valproate have decreased, whereas those for levetiracetam have increased. Except for the top two AED monotherapies, there were marked differences in other monotherapies and in polytherapies between U.S. and UK centers. Future investigations are needed to examine reasons for drug choice.
Introduction
The first reports of antiepileptic drug (AED)-induced birth defects in humans date from the 1960s [1] . For many years, it has been known that the overall risk of major malformations across AEDs is increased about two-to threefold [2] . Higher dosages, higher blood levels, and polytherapy are associated with higher risks. In addition to anatomical teratogenesis, concerns have also been raised by animal and human studies that AEDs can produce behavioral teratogenesis, which results in cognitive impairment [3] . With the exception of an approximately 1.5% risk of neural tube defects with in utero valproate exposure [2] , there has been little information available on differential AED risks until recently. The prior paucity of information on differential AED risks is reflected in the last published consensus guidelines of the American Academy of Neurology [4] , American College of Obstetricians and Gynecologists [5] , and International League Against Epilepsy [6] . None of these guidelines delineated differential teratogenetic risks across AEDs.
In recent years, there has been a marked increase in information concerning AED teratogenesis based in large part on the formation of multiple pregnancy registries. A consistent finding has emerged indicating that valproate poses an increased risk to the unborn child [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . This differential risk includes both anatomical and behavioral teratogenetic defects, both of which are dose dependent. Six of the studies implicating an increased risk for valproate were published in 2004, with an additional three in 2005. A recent meta-analysis examining AED anatomical teratogenesis indicated that in utero valproate exposure is associated with a 10.73% (95% CI: 8.16-13.29) risk of major malformations, which occurred across multiple body systems [20] . In utero valproate exposure has also been associated with reduced cognitive abilities in four patient cohorts [8] [9] [10] 19] . This suggests that the risk of valproate extends throughout pregnancy, as the risk of anatomical defects is due to first-trimester exposure [2] , and the risk for behavioral defects appears to be due primarily to third-trimester exposure [3] .
Data for other AEDs are less clear or even completely lacking. Based on fewer studies, there appears to be an increased risk of anatomical and behavioral defects with phenobarbital [21, 22] . Overall risks for carbamazepine and lamotrigine exposure are low [16] [17] [18] 23] , but a risk for cleft lip/palate has been reported for both. According to one study [24] and preliminary [25] results from another, the risk of cleft lip/palate is increased with carbamazepine. In one report on lamotrigine, an increased risk of cleft lip/palate was observed [23] , but another study found contradictory results for lamotrigine [26] . In addition, one registry has described a dosedependent effect for lamotrigine [16] , but this was not confirmed by two other studies [23, 27] . Preliminary studies with levetiracetam suggest low risk, but small sample sizes limit conclusions [28] . Small sizes and mixed results limit conclusions about topiramate [29, 30] . In utero phenytoin exposure has been reported to impair cognitive functions in three studies [31] [32] [33] that did not control for maternal IQ, but phenytoin was not statistically worse than carbamazepine or lamotrigine according to the results of a prospective study [19] that did control for maternal IQ. Because the most compelling findings for human teratogenesis are those found consistently across different studies, the risks for AEDs other than valproate remain uncertain.
Published information is lacking on current AED prescribing patterns for women of childbearing age with epilepsy. The purpose of the present study was to examine changes in prescription practices at tertiary epilepsy centers as a result of the demonstrated increased risks for valproate and the emerging information on teratogenetic risks of other AEDs.
Methods
Both the original Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) study and the 2007 survey were approved by the institutional review board at each participating center and were conducted in accordance with the ethical standards delineated in the 1964 Declaration of Helsinki. The NEAD Study is a prospective observational National Institutes of Health (NIH)funded investigation, and enrolled 333 mother/child pairs during pregnancy from October 1999 to February 2004 across 26 epilepsy centers in the United States and United Kingdom [16] . The primary aim of the NEAD Study was to determine differential long-term neurodevelopmental effects of in utero AED exposure. The study focused on the four most commonly used AED monotherapies (i.e., carbamazepine, lamotrigine, phenytoin, or valproate) during that period, because these four AEDs were by far the most commonly used AEDs at these centers. The number of women on other AED monotherapies was too small to generate adequate samples. 
Participants
The 2007 survey included women with epilepsy, between the ages of 12 and 45, who were pregnant or who were of childbearing age. The NEAD Study included pregnant women on one of the four aforementioned AED monotherapies.
Procedure
Surveys were filled out by local investigators who obtained the information from the clinical records of patients presenting to their epilepsy clinics who met the above eligibility criteria during the study period. The diagnosis of epilepsy was confirmed, and the following information was obtained from the medical records: age, pregnancy status, and number/types of current AED treatments.
Statistical analyses
Descriptive summary statistical information was calculated. X 2 contingency analyses were conducted comparing distributions of: (1) treatment (i.e., no AED, monotherapy, polytherapy) for pregnant versus nonpregnant women, (2) types of AED monotherapy for pregnant versus nonpregnant women, (3) monotherapy for the four AEDs in the NEAD Study (across the eight centers in the present survey) compared with the same four drugs in pregnant women from the 2007 survey, and (4) types of AED monotherapy for the United States versus the United Kingdom.
Results
There were a total of 932 women in the 2007 survey; 793 were from the United States, and 139 were from the United Kingdom. The mean age of the women was 30 years (±8.7). Pregnant women constituted 11% of the sample. See Table 1 for the survey distribution of monotherapy, polytherapy, and no AED exposure, which differed between pregnant and nonpregnant women (X 2 = 37.0, P ≤ 0.000). Pregnant women were more likely to be on no AED or monotherapy, but less likely to be on polytherapy than nonpregnant women. AED monotherapy did not differ significantly between pregnant and nonpregnant women (X 2 = 14.2, P = 0.076). Monotherapies employed differed between the United States and United Kingdom (X 2 = 28.0, P ≤ 0.000) (see Supplementary Table 1 ). Lamotrigine was the most commonly used AED in both countries, but levetiracetam, oxcarbazepine, topiramate, and zonisamide were used more often in the United States, whereas carbamazepine and valproate were used more often in the United Kingdom.
The four AEDs used in monotherapy in the NEAD Study (1999) (2000) (2001) (2002) (2003) (2004) changed in the eight centers by the 2007 survey (X 2 = 22.0, P ≤ 0.0001) (see Table 2 ). There was a relative increase in lamotrigine use and a relative decrease in the use of carbamazepine, phenytoin, and valproate in 2007 compared with the earlier period. Across the entire 2007 survey, the top four AEDs in order of decreasing use were lamotrigine, levetiracetam, carbamazepine and topiramate compared to carbamazepine, lamotrigine, phenytoin, and valproate during NEAD enrollment.
Polytherapy was used in 41% of the survey sample overall. Of those on polytherapy, 65% were on two AEDs, 28% on three AEDs, and 7% on four or more AEDs. Polytherapy choices varied widely (see Supplementary Table 2 ). The most common two-AED combination in the United States (i.e., lamotrigine-levetiracetam) constituted 20% of two AED polytherapies in the United States, but only 3% in the United Kingdom. The most common two-AED polytherapy in the United Kingdom (i.e., carbamazepine-levetiracetam) constituted 18% of two-AED polytherapies in the United Kingdom, but only 5% in the United States. Further, 44% of two-AED polytherapies comprised less than 4% of the two-AED polytherapies on an individual basis.
Discussion
This report describes changes over the past several years in AED prescription practices in women with epilepsy at epilepsy specialty centers in the United States and United Kingdom. During the original recruitment period for the NEAD Study (October 1999 to February 2004), the four most commonly used AEDs in descending order in pregnant women with epilepsy at epilepsy specialty centers were carbamazepine, lamotrigine, valproate, and phenytoin [16, 19] . By 2007, the four most commonly used AEDs in women of childbearing age with epilepsy in the specialty centers were lamotrigine, levetiracetam, carbamazepine, and topiramate.
Given that multiple publications have described an association with in utero valproate exposure, it is not surprising that valproate use declined in women being treated at epilepsy specialty centers. Less clear from an evidence-based medical approach is the apparent decline in carbamazepine use despite its relatively mild adverse teratogenesis profile, which is similar to that of lamotrigine. Carbamazepine was actually used by the largest number of patients in pregnancy-related studies prior to 2007. The causes of the reduced usage of carbamazepine are unclear, but may include tolerability (e.g., cognitive and other side effects), drug interactions, or marketing factors. Phenytoin use has decreased by an even larger proportion at epilepsy specialty centers. The increase in levetiracetam use may be based on several factors including: the promising but very limited preliminary human birth defect data published by the UK Registry in 2006 [28] and general tolerability, safety, efficacy, and lack of neuronal apoptosis in animal studies [34, 35] . However, it should be reemphasized that the present teratogenic data for levetiracetam, like those for many AEDs, are inadequate to be certain.
Compared with nonpregnant women of childbearing age, pregnant women were more likely to be on AED monotherapy than polytherapy. Although this may be an attempt to avoid the risks of polytherapy during pregnancy, it may also reflect increased difficulty in conception in women on polytherapy because of the AEDs or the increased severity of epilepsy.
Although lamotrigine was the most common AED monotherapy in the United States and United Kingdom, other monotherapies differed across the two countries. Even greater variability was seen in the choice of polytherapies. For example, examination of the two-AED polytherapy combinations in the survey reveals that the top nine AED combinations ranged from 4 to 18% individually of all two-AED combinations, and that the remaining combinations, which were all less than 4% each individually, constituted 44% of all two-AED polytherapy combinations. This variability likely reflects a lack of evidence-based medical data to inform and direct therapy.
Strengths of our study include repeated assessments of AED use in a set of epilepsy specialty centers. Our study has several limitations. Only 8 of the original 25 epilepsy specialty centers were included in the 2007 survey, but these 8 centers enrolled 54% of the original subjects, and the distribution of AEDs in 1999-2004 in these centers was similar to the entire sample. In 2007, we assessed primarily use of AEDs in women with epilepsy of childbearing age and not specifically women with epilepsy of childbearing potential. Thus, AED selection might differ in those of childbearing age who do not have childbearing potential. Another limitation is that our study does not specifically address the reasons for the changes (or absence of changes) seen over this period.
The reported data provide a window into current AED use in women, but the findings may not apply to all epilepsy specialty centers, much less the entire general medical population. Although data from 2007 are not yet available, a general medical population estimate is available from public-use data for the years 2000-2006 from the National Center for Health Statistics [36] , which includes the National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS). These data reveal that the two most commonly used AEDs for epilepsy or seizures in women of childbearing age were phenytoin and valproate across the entire period 2000-2006. The data from the general medical population and the NEAD centers are not directly comparable because they differ in last year of assessment (2006 vs 2007), and there is a lack of information on the patient populations (e.g., pregnancy, co-morbidities, refractoriness). Despite these limitations, data from the general medical population differ markedly from data from the tertiary centers at the beginning of the century and suggest that the new information on teratogenetic risks for valproate has had little effect on the prescription practices for women of childbearing age in the general medical population through 2006.
Factors that may affect drug choice include efficacy, approved indications, side effects (including AED teratogenesis), drug interactions, past medical history, present comorbidities, costs, and marketing. The interaction of multiple factors, which are at times conflicting, can make drug choice difficult for an individual patient. Further complicating drug choice is an inadequate database for many factors. For example, direct head-to-head comparisons of efficacy and side effects are not available for most AEDs. In the absence of adequate evidence-based data, rational therapeutic practice is a challenge. Nevertheless, the factors driving changes in AED prescriptions to women of childbearing age are not completely clear.
The recent increase in information concerning AED teratogenesis improves our ability to care for women of childbearing potential, but it also complicates therapeutic decisions. Previous guidelines have simply recommended that physicians choose the most effective AED for the individual woman. Now physicians must consider factors related to teratogenetic risks for specific AEDs, although the evidence for some risks and many AEDs remains uncertain. Even the definite increased risk of valproate has to be balanced against considerations of efficacy [37] . Neither teratogenesis nor efficacy for seizure control can be predicted on an individual patient basis. We have previously recommended that valproate not be used as a first-line AED in women of childbearing potential, because the failure to control seizures may be corrected by altering the AED, but the occurrence of teratogenesis is frequently irreversible and results in lifelong disability [17] . If valproate is used in a woman of childbearing potential, the lowest effective dose should be employed, as valproate's teratogenic risk is dose dependent. The informed consent process must include a discussion of these various factors as they relate to the individual woman. The discussion should occur when the AED is first prescribed and should provide advice concerning the certainty of the information available so that the patient can participate fully in the decision process.
